​

Alvotech (ALVO) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChartTranscripts

Alvotech Revenue Highlights

Latest Revenue (Y)

$91.43M

Latest Revenue (Q)

$12.43M

Main Segment (Y)

Humira

Main Geography (Y)

UNITED STATES

Alvotech Revenue by Period

Alvotech Revenue by Year

DateRevenueChange
2023-12-31$91.43M10.12%
2022-12-31$83.03M125.79%
2021-12-31$36.77M-44.80%
2020-12-31$66.62M108.71%
2019-12-31$31.92M-

Alvotech generated $91.43M in revenue during NA 2023, up 10.12% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Alvotech Revenue by Quarter

DateRevenueChange
2024-03-31$12.43M-76.72%
2023-12-31$53.39M200.13%
2023-08-31$17.79M305.12%
2023-06-30$4.39M-72.32%
2023-03-31$15.86M-33.51%
2022-12-31$23.86M25.22%
2022-09-30$19.05M-51.97%
2022-06-30$39.67M8675.66%
2022-03-31$452.00K-98.70%
2021-12-31$34.76M6385.82%
2021-09-30$536.00K-94.17%
2021-06-30$9.19M-
2021-03-31$9.19M-44.80%
2020-12-31$16.65M-
2020-09-30$16.65M-
2020-06-30$16.65M-
2020-03-31$16.65M108.71%
2019-12-31$7.98M-
2019-09-30$7.98M-
2019-06-30$7.98M-
2019-03-31$7.98M-

Alvotech generated $12.43M in revenue during Q1 2024, up -76.72% compared to the previous quarter, and up 52.10% compared to the same period a year ago.

Alvotech Revenue Breakdown

Alvotech Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23
Humira$12.20B

Alvotech's latest annual revenue breakdown by segment (product or service), as of Dec 23: Humira (100.00%).

Alvotech Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24Dec 23Dec 22
Europe$157.59M$63.51M$39.43M
Rest Of The World$59.06M--
UNITED STATES$273.04M--
North America-$18.31M$30.78M
Asia And Other-$9.62M-
Other Geographical Area--$6.02M
Asia--$6.80M

Alvotech's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (55.76%), Europe (32.18%), and Rest Of The World (12.06%).

Alvotech Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
ALKSAlkermes$1.56B$378.14M
AMPHAmphastar Pharmaceuticals$712.81M$188.82M
PCRXPacira BioSciences$700.97M$168.57M
ITCIIntra-Cellular Therapies$680.85M$175.38M
COLLCollegium Pharmaceutical$631.45M$159.30M
ANIPANI Pharmaceuticals$614.38M$148.33M
LFCRLifecore Biomedical$128.26M$35.15M
ASRTAssertio$124.96M$29.20M
ALVOAlvotech$91.43M$12.43M
CYTHCyclo Therapeutics$1.08M$123.10K

ALVO Revenue FAQ

What is Alvotech’s yearly revenue?

Alvotech's yearly revenue for 2023 was $91.43M, representing an increase of 10.12% compared to 2022. The company's yearly revenue for 2022 was $83.03M, representing an increase of 125.79% compared to 2021. ALVO's yearly revenue for 2021 was $36.77M, representing a decrease of -44.80% compared to 2020.

What is Alvotech’s quarterly revenue?

Alvotech's quarterly revenue for Q1 2024 was $12.43M, a -76.72% decrease from the previous quarter (Q4 2023), and a -21.65% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $53.39M, a 200.13% increase from the previous quarter (Q3 2023), and a 123.78% increase year-over-year (Q4 2022). ALVO's quarterly revenue for Q3 2023 was $17.79M, a 305.12% increase from the previous quarter (Q2 2023), and a -6.63% decrease year-over-year (Q3 2022).

What is Alvotech’s revenue growth rate?

Alvotech's revenue growth rate for the last 3 years (2021-2023) was 148.65%, and for the last 5 years (2019-2023) was 186.47%.

What are Alvotech’s revenue streams?

Alvotech's revenue streams in c 23 are Humira

What is Alvotech’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Alvotech was Humira. This segment made a revenue of $12.2B, representing 100.00% of the company's total revenue.